J Diabetes Investig 2017; 8: 518--534

Introduction {#jdi12605-sec-0005}
============

The number of people with diabetes worldwide is increasing, and is estimated to reach 642 million by 2040[1](#jdi12605-bib-0001){ref-type="ref"}. This increase in prevalence will be particularly pronounced in Asia, which is expected to account for more than 60% of the world\'s diabetic population within the coming decades[2](#jdi12605-bib-0002){ref-type="ref"}. Clearly, research and dissemination of research findings, and examining the efficacy and safety of diabetes treatments is critical for optimizing treatment strategies required to address the worsening diabetes pandemic. One important factor that should be considered in such research is race/ethnicity, which can affect the characteristics of patients with diabetes and, possibly, their response to treatment. For instance, differences in genetic susceptibility, phenotype and underlying pathophysiology, age of onset, and body mass index (BMI) have been reported/suggested between Asians and Caucasians with diabetes[3](#jdi12605-bib-0003){ref-type="ref"}, [4](#jdi12605-bib-0004){ref-type="ref"}, [5](#jdi12605-bib-0005){ref-type="ref"}, [6](#jdi12605-bib-0006){ref-type="ref"}, [7](#jdi12605-bib-0007){ref-type="ref"}. Furthermore, there are differences in glycemic indices and glycemic load related to diet, whereby postprandial hyperglycemia plays a more prominent role in modulating glycated hemoglobin (HbA1c) in Asians than Caucasians[8](#jdi12605-bib-0008){ref-type="ref"}, [9](#jdi12605-bib-0009){ref-type="ref"}. Given these differences and the projected increase in the prevalence of diabetes in the region, studies assessing the efficacy and safety of diabetes treatments in Asians are of obvious importance.

Most patients with type 2 diabetes will require treatment with insulin and, with disease progression, intensification of insulin therapy. Basal insulin or premixed insulin analogs are typically prescribed for initiation (depending on the country), whereas basal--bolus insulin or premixed insulin analogs are typically prescribed for intensification. Of these treatment options, premixed insulin analogs are widely used in some East Asian countries. Indeed, approximately two‐thirds of Chinese patients taking oral antihyperglycemic drugs and insulin use insulin in the form of premixed insulin[10](#jdi12605-bib-0010){ref-type="ref"}, and approximately one‐third of Japanese patients initiate insulin therapy with premixed insulin[11](#jdi12605-bib-0011){ref-type="ref"}. Despite the wide (and recommended[12](#jdi12605-bib-0012){ref-type="ref"}, [13](#jdi12605-bib-0013){ref-type="ref"}) use of premixed insulins, there is relatively little information in the literature on their efficacy and safety in Asian populations. Furthermore, although the findings from a number of randomized controlled trials have been published, to date, there have been no systematic collation/meta‐analyses of findings from randomized controlled trials.

The primary aim of the present systematic review was to review the relative effectiveness and safety of premixed insulins in Asians, specifically East Asians, with type 2 diabetes as determined in randomized controlled trials. Secondary aims were to compare the efficacy and safety of premixed insulin analogs with basal or basal--bolus insulin, and between East Asians and Caucasians.

Materials and Methods {#jdi12605-sec-0006}
=====================

Eligibility criteria {#jdi12605-sec-0007}
--------------------

### Study design and participants {#jdi12605-sec-0008}

Published evidence from randomized controlled trials involving patients with type 2 diabetes and a minimum of 12 weeks of treatment (and meta‐analyses of such trials) was included. Evidence from other study designs was excluded. Narrative/systematic reviews were also excluded; however, reference lists from such articles were screened to identify potentially eligible studies not detected in the literature search.

### Interventions {#jdi12605-sec-0009}

Studies involving treatment with any premixed insulin analog were included. For studies comparing premixed insulin analogs with other insulin treatments, other treatments were restricted to any basal insulin, basal--bolus insulin or premixed human insulin.

### Outcome measures {#jdi12605-sec-0010}

Outcome measures were collected as reported. Efficacy outcomes were HbA1c, fasting blood glucose/fasting plasma glucose (FPG), self‐monitoring of blood/plasma glucose (SMBG/SMPG) and insulin dose. Safety outcomes were hypoglycemia and bodyweight/BMI.

### Setting {#jdi12605-sec-0011}

Studies carried out in East Asian countries/regions (China, Hong Kong, Japan, Korea, Macao, Mongolia, Taiwan) were included, as were multinational studies where separate results for East Asians and Caucasians were available. Studies reporting outcomes from mixed populations (East Asian and non‐East Asian) or subgroup analyses of patients of East Asian descent/origin living in non‐East Asian countries were excluded.

Information sources {#jdi12605-sec-0012}
-------------------

The following databases were searched (1 January 1995 to 26 November 2015): MEDLINE and Embase via Ovid, The Cochrane Library, and ClinicalTrials.gov.

Search strategy {#jdi12605-sec-0013}
---------------

The databases were searched using search terms (Medical Subject Heading \[MeSH\], EMTREE and/or free text) from three categories: (i) premixed insulin analogs (30% soluble insulin aspart \#bib70% protamine‐crystallized insulin aspart \[BIAsp\]; Humalog; insulin aspart; insulin lispro; insulin mixture\*; lispro; Novolog; Novomix; Novorapid; premixed insulin analog\*; premixed insulin \[\* indicates wild card truncation\]); (ii) East Asia (China; East Asia\*; Hong Kong; Japan; Korea; Macao; Mongolia; Taiwan); and (iii) type 2 diabetes (diabetes mellitus, type 2; non‐insulin dependent diabetes mellitus; T2D\*; type 2 diabetes; type 2 diabetes mellitus).

Where possible, search terms and strategies were individualized to each database. Terms were combined using 'OR' and 'AND'. As an example, MEDLINE was searched using the following strategy: (*insulin aspar*t *\[MeSH\]* OR *insulin lispro \[MeSH\]* OR *BIAsp* OR *Humalog* OR *insulin aspart* OR *insulin lispro* OR *insulin mixture\** OR *lispro* OR *Novolog* OR *Novomix* OR *Novorapid* OR *premixed insulin analog\** OR *premixed insulin*) AND (*China \[MeSH\]* OR *Hong Kong \[MeSH\]* OR *Japan \[MeSH\]* OR *Korea \[MeSH\]* OR *Macao \[MeSH\]* OR *Mongolia \[MeSH\]* OR *Taiwan \[MeSH\]* OR *China* OR *East Asia\** OR *Hong Kong* OR *Japan* OR *Korea* OR *Macao* OR *Mongolia* OR *Taiwan*) AND (*diabetes mellitus, type 2 \[MeSH\]* OR *T2D\** OR *type 2 diabetes* OR *type 2 diabetes mellitus*).

There were no restrictions on language.

Study records {#jdi12605-sec-0014}
-------------

Searches were collated using a bibliography manager, and duplicates were removed. One reviewer screened the title and abstract of each publication identified, and applied the eligibility criteria to identify publications that required further review. All authors were consulted if inclusion was uncertain, and reviewed and approved all articles selected for inclusion. One person extracted all data from the included publications into standardized data tables.

Study characteristics {#jdi12605-sec-0015}
---------------------

Study characteristics collected included publication year, study design, intervention and type of control/comparator, treatment regimen, and source of financial support.

Outcomes {#jdi12605-sec-0016}
--------

The primary efficacy outcome was HbA1c change from baseline to end‐point. Secondary efficacy outcomes were the proportion of patients attaining HbA1c targets, fasting blood glucose/FPG and SMBG/SMPG change from baseline to end‐point, and total daily insulin dose at study end‐point.

The primary safety outcome was the incidence of hypoglycemia. The secondary outcome was the rate of hypoglycemia and bodyweight/BMI change from baseline.

Risk of bias {#jdi12605-sec-0017}
------------

Each study was rated as having a low, high or unclear risk of bias regarding sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias[14](#jdi12605-bib-0014){ref-type="ref"}.

Results {#jdi12605-sec-0018}
=======

Study selection {#jdi12605-sec-0019}
---------------

A total of 536 studies were identified in the search of published literature (Figure [1](#jdi12605-fig-0001){ref-type="fig"}). Of these \#bib165 were duplicates and 356 were excluded. Three additional studies were identified (including two[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"} that had been submitted, but not published at the time of the literature search); hence 18 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} from the literature were included in the review. Three eligible studies[33](#jdi12605-bib-0033){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"} were identified in the search of ClinicalTrials.gov and included.

![Literature search flow diagram.](JDI-8-518-g001){#jdi12605-fig-0001}

Study characteristics {#jdi12605-sec-0020}
---------------------

Most studies (*n* = 14)[15](#jdi12605-bib-0015){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [33](#jdi12605-bib-0033){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"} were carried out in China or Japan; there were four multicountry studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} (Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}).

###### 

Summary of study characteristics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author and year (or CT.gov identifier) Countries/regions   Study design Duration                   Key eligibility criteria                                                                                                                    Previous treatment                                                      Study treatment (no. patients)                                                   Treatment regimen                                                                                                                                                                                                                                                                             Sponsor/funding
  ---------------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  *Initiation of insulin therapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Masuda (2008)[17](#jdi12605-bib-0017){ref-type="ref"}\           R, OL\                                  HbA1c ≥7.0%, insulin naïve                                                                                                                  OADs                                                                    LM50 (*n* = 14)\                                                                 LM50 twice daily\                                                                                                                                                                                                                                                                             NR
  Japan                                                            12 weeks                                                                                                                                                                                                                                                    NPH insulin + insulin lispro (*n* = 14)                                          NPH insulin at bedtime + preprandial insulin lispro\                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                First 10 days\                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated to achieve FPG \<130 mg/dL and 2 h postprandial PG \<180 mg/dL\                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                \>10 days\                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated to achieve HbA1c \<7.0% with minimal hypoglycemia                                                                                                                                                                                                                          

  Ji (2016)[15](#jdi12605-bib-0015){ref-type="ref"}\               R, OL\                                  HbA1c ≥7.0 and ≤11.0%, insulin naïve                                                                                                        OADs                                                                    LM25\                                                                            LM25 once daily before dinner, progressing to thrice daily (doses titrated to achieve FBG/pre‐evening meal BG 4.5--6.0 mmol/L)\                                                                                                                                                               Eli Lilly
  China, Korea                                                     48 weeks                                                                                                                                                                                                                                                    East Asian (*n* = 45)\                                                           Insulin glargine once daily at bedtime (dose titrated to achieve FBG 4.5--6.0 mmol/L) + insulin lispro up to thrice daily (doses titrated to achieve premeal/bedtime BG 4.5--6.0 mmol/L)                                                                                                      
                                                                                                                                                                                                                                                                                                                               Caucasian (*n* = 69)\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                               Insulin glargine + insulin lispro\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                               East Asian (*n* = 44)\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                               Caucasian (*n* = 61)\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                                                                                                                                                                                                                                                                                                                            

  Zhang (2010)[18](#jdi12605-bib-0018){ref-type="ref"}\            R, OL, cross‐over\                      FPG ≥7 mmol/L,\                                                                                                                             OADs                                                                    LM50 (*n* = 30)\                                                                 Induction (10 days)\                                                                                                                                                                                                                                                                          NR
  China                                                            12 weeks on each arm (24 weeks total)   PPG ≥11.1 mmol/L                                                                                                                                                                                                    Premixed human insulin 70/30 (*n* = 30)\                                         All patients: Premixed human insulin 70/30 (starting dose: 0.5--0.6 IU/kg)\                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                               MET (obese patients only)                                                        Week 1--12 and Week 13--24\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                LM50 or premixed human insulin 70/30 (doses titrated to achieve FPG 5--8 mmol/L and PPG 6--10 mmol/L)                                                                                                                                                                                         

  Miyashita (2008)[19](#jdi12605-bib-0019){ref-type="ref"}\        R, OL\                                  HbA1c ≥8.0                                                                                                                                  OADs                                                                    BIAsp30 (*n* = 21)\                                                              BIAsp30 before breakfast and dinner\                                                                                                                                                                                                                                                          NR
  Japan                                                            6 months                                                                                                                                                                                                                                                    NPH insulin + insulin aspart (*n* = 21)\                                         NPH insulin + insulin aspart at night on an on‐demand basis\                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                               Continuation of MET and TZDs (all patients)                                      First 7 days:\                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated every 2--3 days to achieve fasting glucose \<130 mg/dL and 2 h postprandial glucose \<180 mg/dL\                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                \>7 days:\                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated monthly to achieve HbA1c \<6.5%                                                                                                                                                                                                                                            

  Hirao (2009)[20](#jdi12605-bib-0020){ref-type="ref"}\            R, OL\                                  HbA1c ≥8.0, insulin naïve                                                                                                                   OADs                                                                    BIAsp30 (*n* = 80)\                                                              BIAsp30 twice daily\                                                                                                                                                                                                                                                                          Japan Diabetes Foundation
  Japan                                                            6 months                                                                                                                                                                                                                                                    Insulin aspart ± NPH insulin (*n* = 80)[†](#jdi12605-note-0001){ref-type="fn"}   Insulin aspart thrice daily[‡](#jdi12605-note-0001){ref-type="fn"}\                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated to achieve HbA1c \<7.0%                                                                                                                                                                                                                                                    

  Lee (2011)[31](#jdi12605-bib-0031){ref-type="ref"}\              R, OL\                                  Previous SU treatment, HbA1c \>7.5%, insulin naïve                                                                                          SU                                                                      BIAsp30 (*n* = 59)\                                                              Once daily (doses titrated to achieve fasting glucose \<6.1 mmol/L without significant hypoglycemia)\                                                                                                                                                                                         Yonsei University\
  Korea                                                            16 weeks                                                                                                                                                                                                                                                    Insulin detemir (*n* = 61)\                                                      After 3 weeks, patients with glycated albumin ≤20% or who had major or frequent hypoglycemia switched to twice‐daily BIAsp30 before breakfast and dinner (doses titrated to achieve fasting glucose 6.1 mmol/L and 2 h postprandial glucose of 10 mmol/L, without significant hypoglycemia)   College of Medicine
                                                                                                                                                                                                                                                                                                                               Continuation non‐SU OADs\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                               (all patients)                                                                                                                                                                                                                                                                                                                                                                 

  Yang (2013)[21](#jdi12605-bib-0021){ref-type="ref"}\             R, OL\                                  HbA1c ≥7.0 and ≤10.0%, FPG ≥6.1 mmol/L, insulin naïve                                                                                       OADs                                                                    BIAsp30 (*n* = 261)\                                                             Once daily (doses titrated to achieve prebreakfast FPG 5.0--6.1 mmol/L)\                                                                                                                                                                                                                      Novo Nordisk
  China, Japan                                                     24 weeks                                                                                                                                                                                                                                                    Insulin glargine (*n* = 260)\                                                    GLIM 4 mg/day, MET 1 \#bib500 or 2 \#bib500 mg/day                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                               GLIM + MET (all patients)                                                                                                                                                                                                                                                                                                                                                      

  Zafar (2015)[22](#jdi12605-bib-0022){ref-type="ref"}\            R, OL\                                  HbA1c ≥7.5%, FBG ≥7.8 mmol/L, insulin naïve                                                                                                 OADs                                                                    LM50 (*n* = 73)\                                                                 Before breakfast & dinner (doses titrated to achieve FBG ≥4.4 and ≤6.1 mmol/L)                                                                                                                                                                                                                Ministry of Education, People\'s Republic of China
  China                                                            12 weeks                                                                                                                                                                                                                                                    LM25 (*n* = 73)                                                                                                                                                                                                                                                                                                                                                                

  Su (2015)[23](#jdi12605-bib-0023){ref-type="ref"}\               R, OL\                                  HbA1c ≥7.0 and ≤11.0%                                                                                                                       OADs                                                                    LM25 (*n* = 80)\                                                                 Before breakfast & dinner (doses titrated to achieve FBG \>3.9 and ≤6.1 mmol/L)                                                                                                                                                                                                               Eli Lilly
  China                                                            26 weeks                                                                                                                                                                                                                                                    LM50 (*n* = 76)                                                                                                                                                                                                                                                                                                                                                                

  NCT01147627[33](#jdi12605-bib-0033){ref-type="ref"}\             R, OL\                                  HbA1c 7.0--10.0%, drug treatment naïve                                                                                                      None                                                                    LM25 (*n* = 138)[§](#jdi12605-note-0001){ref-type="fn"}                          Before breakfast and dinner (50:50%)\                                                                                                                                                                                                                                                         Sun Yat‐sen University
  China                                                            48 weeks                                                                                                                                                                                                                                                                                                                                     Doses titrated following a forced schedule per BG before breakfast and dinner                                                                                                                                                                                                                 

  Domeki (2014)[24](#jdi12605-bib-0024){ref-type="ref"}\           R, OL\                                  HbA1c ≥8.4%, insulin naïve                                                                                                                  OADs                                                                    LM50 (*n* = 36)\                                                                 Before dinner (dose titrated to achieve HbA1c \<7.4%) + injections before breakfast and before lunch after 16 and 32 weeks, respectively, if HbA1c \<7.4%                                                                                                                                     NR
  Japan                                                            48 weeks                                                                                                                                                                                                                                                    BIAsp30 (*n* = 36)\                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                                                                                                                                                                                                                                                                                                                            

  Yang (2008)[25](#jdi12605-bib-0025){ref-type="ref"}\             R, OL\                                  HbA1c ≥7.5% and FBG ≥7.8 mmol/L, insulin naïve                                                                                              OADs                                                                    BIAsp30 × 2 (*n* = 160)\                                                         BIAsp30 before breakfast & dinner (50:50%)\                                                                                                                                                                                                                                                   Novo Nordisk
  China                                                            24 weeks                                                                                                                                                                                                                                                    BIAsp30 × 3 (*n* = 161)\                                                         BIAsp30 before breakfast, lunch & dinner (25:25:50%)\                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                              All doses titrated to achieve premeal BG 4.4‐6.1 mmol/L                                                                                                                                                                                                                                       

  Ebato (2009)[26](#jdi12605-bib-0026){ref-type="ref"}\            R, OL\                                  HbA1c \>8.0%, insulin naïve                                                                                                                 OADs                                                                    BIAsp30 + GLIM (*n* = 14)\                                                       Week 1--24\                                                                                                                                                                                                                                                                                   Novo Nordisk
  Japan                                                            48 weeks                                                                                                                                                                                                                                                    BIAsp30 (*n* = 12)\                                                              BIAsp30 before breakfast (4 U, from week 8 onwards, +2 U if before dinner BG ≥200 mg/dL at week 10, titrated to achieve before dinner BG 121--180 mg/dL from week 11--24)\                                                                                                                    
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                              GLIM 3 mg/day\                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                Week 25--‐48[¶](#jdi12605-note-0001){ref-type="fn"}\                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                BIAsp30 before breakfast & dinner (doses titrated to achieve before dinner & before breakfast BG, respectively,\                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                101--150 mg/dL) ± GLIM 3 mg/day                                                                                                                                                                                                                                                               

  Jung (2014)[27](#jdi12605-bib-0027){ref-type="ref"}\             R, OL\                                  HbA1c ≥7.5%, insulin naive                                                                                                                  OADs                                                                    BIAsp30 (morning : evening ratio)\                                               Before breakfast & dinner (doses titrated to achieve preprandial BG ≥4.4 and ≤6.1 mmol/L)                                                                                                                                                                                                     NR
  Korea                                                            24 weeks                                                                                                                                                                                                                                                    50:50% (*n* = 33)\                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                               55:45% (*n* = 34)\                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                               60:40% (*n* = 33)\                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                               Continuation of OADs, except SU (all patients)                                                                                                                                                                                                                                                                                                                                 

  *Intensification of insulin therapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Yamada (2007)[28](#jdi12605-bib-0028){ref-type="ref"}\           R, OL\                                  HbA1c \>6.5%, treatment with 70/30 or 50/50 premixed insulin twice daily for ≥3 months                                                      Premixed human insulin                                                  LM50 (*n* = 15)\                                                                 LM50 twice daily\                                                                                                                                                                                                                                                                             NR
  Japan                                                            4 months                                                                                                                                                                                                                                                    Premixed human insulin (*n* = 15)                                                Premixed human insulin twice daily\                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated to achieve postprandial BG \<180 mg/dL and FBG \<130 mg/dL                                                                                                                                                                                                                 

  Jia (2015)[32](#jdi12605-bib-0032){ref-type="ref"}\              R, OL\                                  HbA1c 7.0--12.0% on twice‐daily premixed insulin                                                                                            Premixed insulin ± OADs                                                 LM50 + LM25 (*n* = 197)\                                                         LM50 before breakfast & lunch + LM25 before dinner\                                                                                                                                                                                                                                           Eli Lilly
  China, Taiwan, Korea                                             24 weeks                                                                                                                                                                                                                                                    Insulin glargine + insulin lispro (*n* = 202)\                                   Insulin glargine at bedtime + insulin lispro before each meal\                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                              All doses titrated to achieve preprandial BG \<6.1 mmol/L and 2 h postprandial BG \<7.8 mmol/L without hypoglycemia                                                                                                                                                                           

  Jeong (2016)[16](#jdi12605-bib-0016){ref-type="ref"}\            R, OL, non‐inferiority\                 HbA1c ≥7.5 and ≤10.5%, FPG ≤6.7 mmol/L                                                                                                      Insulin glargine, OADs                                                  LM25\                                                                            LM25 before breakfast & dinner (doses adjusted to achieve FBG or predinner plasma‐equivalent BG \<6.1 mmol/L)\                                                                                                                                                                                Eli Lilly
  China, Korea                                                     24 weeks                                                                                                                                                                                                                                                    East Asian (*n* = 40)\                                                           Insulin glargine at bedtime (doses adjusted to achieve premeal plasma‐equivalent BG 5.6‐6.7 mmol/L) + insulin lispro before main meal (doses adjusted to achieve plasma‐equivalent FBG ≤5.5 mmol/L)                                                                                           
                                                                                                                                                                                                                                                                                                                               Caucasian (*n* = 136)\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                               Insulin glargine + insulin lispro\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                               East Asian (*n* = 40)\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                               Caucasian (*n* = 143)\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                               MET and/or PIO (all patients)                                                                                                                                                                                                                                                                                                                                                  

  Jin (2015)[29](#jdi12605-bib-0029){ref-type="ref"}\              R, OL, non‐inferiority\                 HbA1c ≥7.0 and ≤10.0%, and FPG \<130 mg/dL on insulin glargine for ≥12 weeks                                                                Insulin glargine + OADs                                                 BIAsp30 (*n* = 83)\                                                              BIAsp before breakfast & dinner (doses titrated to achieve FPG 70--100 mg/dL)\                                                                                                                                                                                                                Sanofi Korea
  Korea                                                            24 weeks                                                                                                                                                                                                                                                    Insulin glargine + insulin glulisine (*n* = 78)\                                 Insulin glargine in evening (dose titrated to achieve FPG 70--100 mg/dL) + insulin glulisine before main meal (dose titrated to achieve 2 h postprandial BG ≤140 mg/dL), with second injection added before second main meal for patients with HbA1c \>7% after 12 weeks                      
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                                                                                                                                                                                                                                                                                                                            

  Kadowaki (2010)[30](#jdi12605-bib-0030){ref-type="ref"}\         R, OL, non‐inferiority\                 HbA1c between 7.5 and 10.0%                                                                                                                 Intermediate‐acting, long‐acting human, and/or premixed human insulin   BIAsp70 (*n* = 145)\                                                             BIAsp70 before each main meal\                                                                                                                                                                                                                                                                Novo Nordisk
  Japan                                                            28 weeks                                                                                                                                                                                                                                                    BIAsp30 (*n* = 144)                                                              BIAsp30 before breakfast and dinner[††](#jdi12605-note-0001){ref-type="fn"}\                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                All doses titrated to achieve FPG \<130 mg/dL and 2 h postprandial PG\                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                \<180 mg/dL                                                                                                                                                                                                                                                                                   

  NCT01278160[35](#jdi12605-bib-0035){ref-type="ref"}\             R, OL\                                  HbA1c ≥7%, completed 24 weeks treatment with BIAsp30 or insulin glargine + MET and GLIM in preceding trial                                  BIAsp30 or insulin glargine, OADs                                       BIAsp30 67:33% (*n* = 89)\                                                       BIAsp30 before breakfast & dinner (67:33 or 50:50%)\                                                                                                                                                                                                                                          Novo Nordisk
  China                                                            16 weeks                                                                                                                                                                                                                                                    BIAsp30 50:50% (*n* = 90)\                                                       MET 500 mg/day                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                               MET (all patients)                                                                                                                                                                                                                                                                                                                                                             

  *Switch from premixed human insulin*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NCT01618214[34](#jdi12605-bib-0034){ref-type="ref"}\             R, OL\                                  HbA1c ≥7 and ≤9.5%, treatment with premixed/self‐mixed human insulin + MET ± α‐glucosidase inhibitor, total daily insulin dose \<1.4 U/kg   Premixed human insulin + OADs                                           BIAsp30 patient‐driven titration (*n* = 172)\                                    Twice daily\                                                                                                                                                                                                                                                                                  Novo Nordisk
  China                                                            20 weeks                                                                                                                                                                                                                                                    BIAsp30 investigator‐driven titration (*n* = 172)\                               Doses titrated                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                               Continuation of OADs (all patients)                                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^62.5% of patients in this group received neutral protamine Hagedorn (NPH) insulin; ^‡^Information on NPH insulin dosing not provided; ^§^Comparator groups in this study included patients treated with exenatide or pioglitazone and were therefore not eligible for inclusion in this review; ^¶^Patients with glycated hemoglobin (HbA1c) \<7.0% at week 24 were excluded; ^††^Patients who failed to achieve the target prebreakfast plasma glucose (PG) level of \<130 mg/dL at 16 weeks could have their predinner formulation switched to 30% soluble insulin aspart \#bib70% protamine‐crystallized insulin aspart (BIAsp30). BG, blood glucose; BIAsp30 \#bib30% soluble insulin aspart \#bib70% protamine‐crystallised insulin aspart; BIAsp70 \#bib70% soluble insulin aspart \#bib30% protamine‐crystallized insulin aspart; CT.gov, ClinicalTrials.gov; FBG, fasting blood glucose; FPG, fasting plasma glucose; GLIM, glimepiride; LM25 \#bib25% insulin lispro \#bib75% insulin lispro protamine suspension; LM50 \#bib50% insulin lispro \#bib50% insulin lispro protamine suspension; MET, metformin; NR, not reported; OADs, oral antihyperglycemic drugs; OL, open‐label; PIO, pioglitazone; PPG, postprandial glucose; R, randomized; SU, sulfonylurea; TZD, thiazolidinediones.

John Wiley & Sons, Ltd

The studies were generally similar in design, but of variable duration (Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}). All had parallel treatment arms, except for one study[18](#jdi12605-bib-0018){ref-type="ref"} that had a cross‐over design. The duration of treatment ranged from 12 to 48 weeks; however, approximately half of the studies had a duration of 24--28 weeks of treatment.

Most studies (*n* = 15)[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}, [33](#jdi12605-bib-0033){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"} included patients with a minimum HbA1c of ≥7.0 or ≥7.5% (Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}). One study[18](#jdi12605-bib-0018){ref-type="ref"} included patients on the basis of FPG and postprandial plasma glucose concentrations (≥7 and ≥11.1 mmol/L, respectively).

Most studies were of initiation (14 studies)[15](#jdi12605-bib-0015){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}, [33](#jdi12605-bib-0033){ref-type="ref"}, rather than intensification (six studies)[16](#jdi12605-bib-0016){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"}, of insulin therapy (Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}). In one study, patients were switched from premixed human insulin to a premixed insulin analog[34](#jdi12605-bib-0034){ref-type="ref"}.

Premixed insulin analogs used in the studies included the low mixtures 30% soluble insulin aspart \#bib70% protamine‐crystallized insulin aspart (BIAsp30 \#bib12 studies[19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"}); 25% insulin lispro \#bib75% insulin lispro protamine suspension (LM25, six studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}, [33](#jdi12605-bib-0033){ref-type="ref"}); the mid mixture 50% insulin lispro \#bib50% insulin lispro protamine suspension (LM50, seven studies[17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}); and the high mixture 70% soluble insulin aspart \#bib30% protamine--crystallized insulin aspart (BIAsp70, one study[30](#jdi12605-bib-0030){ref-type="ref"}; Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}). Several studies included more than one premixed insulin analog treatment group. Control/comparator interventions included basal--bolus insulin (seven studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}), basal insulin (two studies[21](#jdi12605-bib-0021){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}) and premixed human insulin (two studies[18](#jdi12605-bib-0018){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}). Different premixed insulin analogs or premixed insulin analog treatment regimens were compared in nine studies[22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"}.

Treatment regimens were variable between studies, with doses titrated to achieve blood glucose, plasma glucose and/or HbA1c targets (Table [1](#jdi12605-tbl-0001){ref-type="table-wrap"}). Except for sulfonylureas, prior oral antidiabetic drugs were generally continued during study treatment.

Risk of bias {#jdi12605-sec-0021}
------------

The studies were generally considered to have a high risk of potential bias because of the open‐label design, but a low risk of potential bias because of incomplete outcome data, selective outcome reporting and other sources of bias (Table [2](#jdi12605-tbl-0002){ref-type="table-wrap"}). More than half of the studies provided insufficient information to make adequate assessment of potential bias related to sequence generation, allocation concealment and blinding of outcome assessors.

###### 

Risk of bias assessment
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Efficacy outcomes {#jdi12605-sec-0022}
-----------------

In all studies, HbA1c levels decreased from baseline to end‐point after treatment with premixed insulin analogs (where reported, the difference between baseline and end‐point was generally statistically significant; Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}). The HbA1c mean/least squares mean changes ranged from −0.12 to −4.2% among all studies, −0.16 to −4.2% in studies where patients received initiation of insulin therapy and −0.12 to −1.32% in studies where patients received intensification of insulin therapy.

###### 

Summary of study outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author and year (or CT.gov identifier) Treatment Groups   HbA1c change[†](#jdi12605-note-0003){ref-type="fn"}   \% Patients achieving HbA1c targets            FBG/FPG change[†](#jdi12605-note-0003){ref-type="fn"}                      SMBG/SMPG change[†](#jdi12605-note-0003){ref-type="fn"}                                                                                                                                                                                            Total daily insulin dose at end‐point                                Definition of hypoglycemia Incidence                         Bodyweight/BMI change[†](#jdi12605-note-0003){ref-type="fn"}
  --------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------
  *Initiation of insulin therapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Masuda (2008)[17](#jdi12605-bib-0017){ref-type="ref"}\          −4.2 vs −4.4% (*P* = NR)                              NR                                             FPG\                                                                       NR                                                                                                                                                                                                                                                 0.40 vs 0.45 IU/kg (*P* = NS)                                        Not defined\                                                 BMI\
  LM50 vs NPH insulin + insulin lispro                                                                                                                                 −151 vs −171 mg/dL (*P* = NR)                                                                                                                                                                                                                                                                                                                                                                      NR (P = NS for rate/patient)                                 −0.3 vs +0.2 kg/m^2^(*P* = NS at baseline or end‐point)

  Ji (2016)[15](#jdi12605-bib-0015){ref-type="ref"}\              LS mean\                                              HbA1c \<7%\                                    NR                                                                         NR                                                                                                                                                                                                                                                 East Asian: 0.42 vs 0.46 IU/kg\                                      Doc/undoc sympt, asympt\                                     Bodyweight\
  LM25 vs insulin glargine + insulin lispro                       East Asian:\                                          East Asian: 37.5 vs 36.1%\                                                                                                                                                                                                                                                                                                                                                   Caucasian: 0.57 vs 0.50 IU/kg *P* = NR for East Asian vs Caucasian   *Overall*\                                                   East Asian: +2.95 vs +2.81 kg\
                                                                  −2.03 vs −1.76%\                                      Caucasian: 51.7 vs 48.1%\                                                                                                                                                                                                                                                                                                                                                                                                                         East Asian: 69.8 vs 77.3%\                                   Caucasian: +3.00 vs +3.43 kg\
                                                                  Caucasian:\                                           *P* = NS for East Asian vs Caucasian                                                                                                                                                                                                                                                                                                                                                                                                              Caucasian: 94.1 vs 91.8%\                                    *P* = NR for East Asian vs Caucasian
                                                                  −2.07 vs −2.05%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        *Nocturnal*\                                                 
                                                                  *P* = NS for East Asian vs Caucasian                                                                                                                                                                                                                                                                                                                                                                                                                                                                    East Asian: 41.9 vs 52.3%\                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Caucasian: 83.8 vs 78.7%\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          *Severe*\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          East Asian: 7.0 vs 0%\                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Caucasian: 2.9 vs 4.9%                                       

  Zhang (2010)[18](#jdi12605-bib-0018){ref-type="ref"}\           Week 12\                                              NR                                             FBG[‡](#jdi12605-note-0003){ref-type="fn"}\                                NR                                                                                                                                                                                                                                                 Week 12\                                                             Not defined\                                                 NR
  LM50 vs premixed human insulin                                  −1.72 vs −1.56%\                                                                                     Week 12\                                                                                                                                                                                                                                                                                                                      35.8 vs 40.6 IU\                                                     NR\                                                          
                                                                  Week 24\                                                                                             −0.1 vs −0.3 mmol/L\                                                                                                                                                                                                                                                                                                          Week 24\                                                             (episodes/patient/study period: week 12,\                    
                                                                  −0.16 vs +0.02%                                                                                      Week 24\                                                                                                                                                                                                                                                                                                                      28.8 vs 34.1 IU                                                      6.0 vs 9.9 events; week 24 \#bib3.5 vs 6.8 events)           
                                                                                                                                                                       +0.1 vs −0.2 mmol/L                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Miyashita (2008)[19](#jdi12605-bib-0019){ref-type="ref"}\       −1.9 vs 2.0% (*P* = 0.32 for % change)                NR                                             NR                                                                         7‐point SMBG\                                                                                                                                                                                                                                      0.39 vs 0.44 IU/kg (*P* = NR)                                        NR                                                           NR
  BIAsp30 vs NPH insulin + insulin aspart                                                                                                                                                                                                         No significant differences between groups at any time‐point                                                                                                                                                                                                                                                                                                                          

  Hirao (2009)[20](#jdi12605-bib-0020){ref-type="ref"}\           −2.6 vs −2.6% (*P* = NS)                              HbA1c \<7%: 32.1 vs 32.8% (*P* = NS)\          NR                                                                         NR                                                                                                                                                                                                                                                 NR                                                                   Not defined\                                                 BMI\
  BIAsp30 vs insulin aspart ± NPH insulin                                                                               HbA1c \<6.5%:\                                                                                                                                                                                                                                                                                                                                                                                                                                    Major: 0 vs 0% episodes                                      +1.47 vs +0.69 kg/m^2^ (*P* = 0.013)
                                                                                                                        17.9 vs 16.4% (*P* = NS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Lee (2011)[31](#jdi12605-bib-0031){ref-type="ref"}\             −1.25 vs −0.70 vs −1.75% (*P* = 0.015)                HbA1c ≤7%: 43 vs 36 vs 41% (*P* = 0.928)       NR                                                                         NR                                                                                                                                                                                                                                                 NR                                                                   NR                                                           NR
  BIAsp30 once daily vs insulin detemir vs BIAsp30 twice daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Yang (2013)[21](#jdi12605-bib-0021){ref-type="ref"}\            −0.78 vs −0.65%\                                      HbA1c \<7%: 29.1 vs 30.0% (*P* = 0.858)\       NR                                                                         9‐point SMPG\                                                                                                                                                                                                                                      17.8 vs 18.2 IU (*P* = NR)                                           Doc/undoc sympt, asympt\                                     Bodyweight\
  BIAsp30 vs insulin glargine                                     Non‐inferiority demonstrated                          HbA1c ≤6.5%:\                                                                                                             2 h postdinner, bedtime, & 02.00--04.00 h significantly reduced (*P* \< 0.05) for BIAsp30 vs insulin glargine; before dinner significantly reduced for insulin glargine vs BIAsp30 (*P* = 0.003)                                                                                                                        Overall: 59.4 vs 56.9% (*P* = NR)\                           +1.2 vs +1.4 kg (*P* = 0.548)
                                                                                                                        14.9 vs 14.2% (*P* = 0.801)                                                                                                                                                                                                                                                                                                                                                                                                                       Nocturnal: 18.8 vs 15.0% (*P* = NR)\                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 0 vs 0.4% (*P* = NR)                                 

  Zafar (2015)[22](#jdi12605-bib-0022){ref-type="ref"}\           −4.2 vs −3.6% (*P* \< 0.05)                           NR                                             FBG\                                                                       NR                                                                                                                                                                                                                                                 0.84 vs 0.87 IU/kg (*P* = 0.17)                                      Doc sympt\                                                   Bodyweight\
  LM50 vs LM25                                                                                                                                                         −2.6 vs −1.1 mmol/L (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                  Minor: 6.84 vs 5.48% (*P* = NS)\                             +1.92 vs +2.03 (*P* = NS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Nocturnal: 0 vs 2.74% (*P* = NS)\                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Major: 0 vs 0%                                               

  Su (2015)[23](#jdi12605-bib-0023){ref-type="ref"}\              LS mean\                                              HbA1c \<7%: 45.0 vs 72.4% (*P* = 0.001)\       FBG LS mean\                                                               7‐point SMBG\                                                                                                                                                                                                                                      38.6 vs 36.2 IU (*P* = NS)                                           Doc/undoc sympt, asympt\                                     LS mean\
  LM25 vs LM50                                                    −1.55 vs −2.03% (*P* \< 0.001)                        HbA1c ≤6.5%:\                                  −2.50 vs −2.12 mmol/L (*P* = 0.180)                                        Predinner, postdinner & bedtime significantly reduced (*P* \< 0.05) for LM50 vs LM25                                                                                                                                                                                                                                    Overall: 48.8 vs 48.7% (*P* = NR)\                           Bodyweight\
                                                                                                                        22.5 vs 59.1% (*P* \< 0.001)                                                                                                                                                                                                                                                                                                                                                                                                                      Nocturnal: 13.8 vs 7.9% (*P* = NR)\                          +1.6 vs +1.5 kg (*P* = NS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 0 vs 0%                                              

  NCT01147627[33](#jdi12605-bib-0033){ref-type="ref"}\            −1.74%                                                NR                                             NR                                                                         NR                                                                                                                                                                                                                                                 NR                                                                   NR                                                           NR
  LM25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Domeki (2014)[24](#jdi12605-bib-0024){ref-type="ref"}\          −1.9 vs −1.7% (*P* = NS at baseline & end‐point)      HbA1c \<7.4%: 72.2 vs 66.7% (*P* = NS)         FPG\                                                                       NR                                                                                                                                                                                                                                                 NR                                                                   Not defined\                                                 BMI\
  LM50 vs BIAsp30                                                                                                                                                      −40 vs −33 mol/L (*P* = NS at baseline & end‐point)                                                                                                                                                                                                                                                                                                                                                Overall: 8.3 vs 8.3%\                                        +2.7 vs +6.1 kg/m^2^ (*P* = NS at baseline & end‐point)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 0 vs 0%                                              

  Yang (2008)[25](#jdi12605-bib-0025){ref-type="ref"}\            −2.48 vs −2.81% (*P* \< 0.01)\                        HbA1c \<7%: 51.3 vs 65.8% (*P* \< 0.01)\       NR                                                                         NR                                                                                                                                                                                                                                                 0.82 vs 0.86 IU/kg (*P* = 0.19)                                      Doc sympt\                                                   Bodyweight\
  BIAsp30 × 2 vs ×3                                               ×3 superior to ×2                                     HbA1c ≤6.5%:\                                                                                                                                                                                                                                                                                                                                                                                                                                     Minor: 23 vs 19% (*P* = NS)\                                 +3.87 vs +4.09 kg (*P* = NS)
                                                                                                                        34.4 vs 46.6% (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                                                       Major: 0.63 vs 1.9% (*P* = NS)                               

  Ebato (2009)[26](#jdi12605-bib-0026){ref-type="ref"}\           −2.33 vs −1.18% (*P* = NR)                            HbA1c \<7%: 50.0 vs 8.3% (*P* = NR)            NR                                                                         NR                                                                                                                                                                                                                                                 0.21 vs 0.36 IU/kg (*P* \< 0.05)                                     Doc sympt, asympt\                                           Bodyweight\
  BIAsp30 + GLIM vs BIAsp30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Major: 0 vs 0%                                               No change (data NR)

  Jung (2014)[27](#jdi12605-bib-0027){ref-type="ref"}\            LS mean\                                              HbA1c \<7%: 29.6 vs 25.0 vs 25.9% (*P* = NS)   FPG\                                                                       NR                                                                                                                                                                                                                                                 0.45 vs 0.46 vs 0.54 IU/kg (*P* = 0.142)                             Doc sympt\                                                   Bodyweight\
  BIAsp30 50:50 vs 55:45 vs 60:40                                 −1.27 vs −1.05 vs −1.03 (*P* = 0.623)                                                                −1.1 vs −1.6 vs −1.0 mmol/L (*P* = NS for LS mean changes \[values NR\])                                                                                                                                                                                                                                                                                                                           Overall: 51.6 vs 50.0 vs 53.3% (*P* = 0.965)                 +1.72 vs +0.93 vs\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       +1.89 kg (*P* = NS)

  *Intensification of insulin therapy*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Yamada (2007)[28](#jdi12605-bib-0028){ref-type="ref"}\          −0.35 vs −0.04% (*P* \< 0.05)                         NR                                             FBG\                                                                       NR                                                                                                                                                                                                                                                 0.38 vs 0.37 IU/kg (*P* = NS)                                        Severe: 0 vs 0%                                              BMI\
  LM50 vs premixed human insulin                                                                                                                                       +28.2 vs −5.4 mg/dL (*P* = NS)                                                                                                                                                                                                                                                                                                                                                                                                                                  +0.3 vs −0.2 kg/m^2^ (*P* = NS)

  Jia (2015)[32](#jdi12605-bib-0032){ref-type="ref"}\             LS mean\                                              HbA1c ≤7%: 29.9 vs 34.2% (*P* = 0.392)\        NR                                                                         7‐point SMBG\                                                                                                                                                                                                                                      52.93 vs 53.99 IU (*P* = 0.106)                                      Not defined\                                                 Bodyweight\
  LM50 + LM25 vs insulin glargine + insulin lispro                −1.1 vs −1.1%\                                        HbA1c ≤6.5%: 9.1 vs 11.9% (*P* = NR)                                                                                      Midday 2 h postprandial, evening premeal, & 03.00 h significantly reduced (*P* \< 0.05) for BIAsp30 vs insulin glargine + insulin lispro; Morning premeal significantly reduced for insulin glargine + insulin lispro *vs* BIAsp30 (*P* = 0.002)                                                                        Overall: 55 vs 55% (*P* = 0.148 for rate/30 days)\           +0.8 kg vs +0.7 kg (*P* = NR)
                                                                  Non‐inferiority demonstrated                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Nocturnal: 14 vs 11% (*P* = 0.235 for rate/days)\            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 0 vs 0%                                              

  Jeong (2016)[16](#jdi12605-bib-0016){ref-type="ref"}\           East Asian\                                           HbA1c \<7%\                                    FBG\                                                                       7‐point SMBG\                                                                                                                                                                                                                                      East Asian: 0.56 vs 0.59 IU/kg (*P* = NR)\                           Doc sympt\                                                   Bodyweight\
  LM25 vs insulin glargine + insulin lispro                       −1.3 vs −0.9% (*P* \< 0.001)\                         East Asian: 33.3 vs 22.9% (*P* = NS)\          East Asian:\                                                               Mean change from baseline similar in both arms for both subpopulations                                                                                                                                                                             Caucasian: 0.69 vs 0.67 IU/kg (*P* = NR)                             *Overall*\                                                   East Asian: +0.62 vs +0.51 kg (*P* = NR)\
                                                                  Caucasian\                                            Caucasian: 37.2 vs 34.1% (*P* = NS)\           0.40 vs 0.25 mmol/L (*P* = NS)\                                                                                                                                                                                                                                                                                                                                                                    East Asian: 65.0 vs 82.1% (*P* = NR)\                        Caucasian: 1.77 vs 0.67 kg (*P* = NR)
                                                                  −1.2 vs −1.0% (*P* \< 0.001)                          HbA1c ≤6.5%\                                   Caucasian:\                                                                                                                                                                                                                                                                                                                                                                                        Caucasian: 69.9 vs 64.1% (*P* = NR)\                         
                                                                                                                        East Asian: 17.9 vs 5.7% (*P* = NR)\           0.87 vs 0.74 mmol/L (*P* ≤ 0.01)                                                                                                                                                                                                                                                                                                                                                                   *Nocturnal*\                                                 
                                                                                                                        Caucasian: 16.5 vs 17.1% (*P* = NR)                                                                                                                                                                                                                                                                                                                                                                                                               East Asian: 17.5 vs 17.9% (*P* = NR)\                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Caucasian: 22.8 vs 25.4% (*P* = NR)\                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          *Severe*\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          East Asian: 0 vs 0%\                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Caucasian: 0.7 vs 0% (*P* = NR)                              

  Jin (2015)[29](#jdi12605-bib-0029){ref-type="ref"}\             −1.07 vs −0.91% (*P* = 0.358)\                        HbA1c \<7%: 29.3 vs 33.3% (*P* = 0.773)\       FPG\                                                                       7‐point SMBG\                                                                                                                                                                                                                                      No between group difference (values NR)                              Doc/undoc sympt, asympt\                                     Body weight\
  BIAsp30 vs insulin glargine + insulin glulisine                 Non‐inferiority demonstrated                          HbA1c ≤6.5%:\                                  24.44 vs 3.11 mg/dL (*P* \< 0.001)                                         Before breakfast & 2 h after lunch significantly reduced (*P* \< 0.05) for insulin glargine + insulin glulisine vs BIAsp30                                                                                                                                                                                              *Baseline--*\                                                +1.05 vs +1.22 kg (*P* = 0.537)
                                                                                                                        14.6 vs 14.1% (*P* = 0.794)                                                                                                                                                                                                                                                                                                                                                                                                                       *Week 12*\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Overall: 68.3 vs 88.5% (*P* = 0.002)\                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Nocturnal: 23.2 vs 34.6% (*P* = 0.110)\                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 0 vs 1.3% (*P* = 0.488)\                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          *Week 12--24*\                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Overall: 72.0 vs 69.2% (*P* = 0.230)\                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Nocturnal: 30.5 vs 25.6% (*P* = 0.665)\                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Severe: 1.2 vs 2.6% (*P* = 0.739)                            

  Kadowaki (2010)[30](#jdi12605-bib-0030){ref-type="ref"}\        −1.32 vs −0.99%\                                      HbA1c \<6.5%:\                                 NR                                                                         7‐point SMPG\                                                                                                                                                                                                                                      46.8 vs 38.1 IU/day (*P* = NR)                                       Doc/undoc sympt, asympt\                                     Bodyweight\
  BIAsp70 vs\                                                     Non‐inferiority shown                                 16.0 vs 11.9% (*P* = NR)                                                                                                  Mean PPG increment: 22.8 vs 47.5 mg/dL (*P* = NR)                                                                                                                                                                                                                                                                       Overall: 90.3 vs 88.2% (*P* = NS)\                           +1.94 vs +1.23 kg (*P* = 0.011)
  BIAsp30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Nocturnal: 27.8 vs 47.2% (*P* \< 0.001)\                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Major: 0.7 vs 2.1% (*P* = NS)                                

  NCT01278160[35](#jdi12605-bib-0035){ref-type="ref"}\            LS mean\                                              HbA1c \<7%: 12.4 vs 14.4% (*P* = 0.731)\       NR                                                                         9‐point SMPG\                                                                                                                                                                                                                                      NR                                                                   Doc sympt, asympt\                                           NR
  BIAsp30: 2/3 and 1/3 split vs 1/2 and 1/2 split                 −0.13 vs −0.12                                        HbA1c ≤6.5%:\                                                                                                             No significant differences between groups at any time‐point                                                                                                                                                                                                                                                             NR (*P* = NS for overall, nocturnal & severe no. episodes)   
                                                                                                                        2.2 vs 7.8% (*P* = 0.126)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  *Switch from premixed human insulin*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NCT01618214[34](#jdi12605-bib-0034){ref-type="ref"}\            −1.32 vs −1.31%\                                      HbA1c \<7%:\                                   −1.26 vs −1.48 mmol/L (*P* = NR)                                           NR                                                                                                                                                                                                                                                 NR                                                                   Doc sympt, asympt\                                           NR
  BIAsp30: patient‐driven vs investigator‐driven titration        Non‐inferiority demonstrated                          64.5 vs 58.1% (*P* = NR)\                                                                                                                                                                                                                                                                                                                                                                                                                         NR (rate/year similar for overall and severe)                
                                                                                                                        HbA1c ≤6.5%:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                        35.5 vs 37.2% (*P* = NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Mean change from study baseline to study end‐point, except where indicated. In cases where the change from baseline values were not directly reported, estimates were determined by subtracting the end‐point values from the baseline values; ^‡^Change is the mean change from the end of the induction period to the end of each treatment period. asympt, asymptomatic hypoglycemia; BIAsp30 \#bib30% soluble insulin aspart \#bib70% protamine‐crystallized insulin aspart; BIAsp70 \#bib70% soluble insulin aspart \#bib30% protamine‐crystallized insulin aspart; BMI, body mass index; CT.gov, ClinicalTrials.gov; doc, documented; FBG, fasting blood glucose; FPG, fasting plasma glucose; GLIM, glimepiride; HbA1c, glycated hemoglobin; LM25 \#bib25% insulin lispro \#bib75% insulin lispro protamine suspension; LM50 \#bib50% insulin lispro \#bib50% insulin lispro protamine suspension; LS, least squares; NPH, neutral protamine Hagedorn; NR, values not reported; NS, not significant; PPG, postprandial plasma glucose; SMBG, self‐monitored blood glucose; SMPG, self‐monitored plasma glucose; sympt, symptomatic hypoglycemia; undoc, undocumented.

John Wiley & Sons, Ltd

A total of 15 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"} reported data on the proportion of patients attaining HbA1c targets after treatment with premixed insulin analogs (Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}). The proportion of patients attaining the HbA1c target of ≤7% ranged from 8.3 to 72.4% among all studies, 8.3 to 72.4% in studies where patients received initiation of insulin therapy and 12.4 to 33.3% in studies where patients received intensification of insulin therapy. The proportion of patients attaining the HbA1c target of ≤6.5% ranged from 2.2 to 59.1% among all studies, 14.9 to 59.1% in studies where patients received initiation of insulin therapy and 2.2 to 17.9% in studies where patients received intensification of insulin therapy.

Of the 10 studies reporting data, fasting blood glucose/FPG concentrations decreased from baseline to end‐point in seven studies[17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [34](#jdi12605-bib-0034){ref-type="ref"}, and increased from baseline to end‐point in three studies[16](#jdi12605-bib-0016){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"} after treatment with premixed insulin analogs (Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}; note: few studies statistically compared baseline and end‐point data). Fasting blood glucose/FPG concentrations were decreased from baseline in six studies[17](#jdi12605-bib-0017){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"} where patients received initiation of insulin therapy, increased from baseline in three studies[16](#jdi12605-bib-0016){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"} where patients received intensification of insulin therapy, and decreased from baseline in the study[34](#jdi12605-bib-0034){ref-type="ref"} where patients were switched from premixed human insulin to a premixed insulin analog.

Of the eight studies[16](#jdi12605-bib-0016){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}, [35](#jdi12605-bib-0035){ref-type="ref"} reporting data, SMBG/SMPG concentrations were generally decreased from baseline for each assessment point during the day after treatment with premixed insulin analogs (Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}; note: SMBG/SMPG results from these studies were typically focused on the comparison between treatment groups \[see Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"} for further details\]).

In the 14 studies reporting data, doses were variable and were reported in IU/kg/day (9 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}) or IU/day (6 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [18](#jdi12605-bib-0018){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"}) among patients treated with premixed insulin analogs (Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}). Doses ranged from 0.21 to 0.87 IU/kg/day and 17.8 to 53.99 IU/day among all studies , 0.21 to 0.87 IU/kg/day and from 17.8 to 38.6 IU/day in studies where patients received initiation of insulin, and 0.38 to 0.56 IU/kg/day and from 46.8 to 53.99 IU/day in studies where patients received intensification of insulin.

Safety outcomes {#jdi12605-sec-0023}
---------------

In 14 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [26](#jdi12605-bib-0026){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} reporting data, the incidence of hypoglycemia was highly variable, ranging from 8.3 to 72.0% among all studies, 8.3 to 68.9% in studies where patients received initiation of insulin therapy, and 55 to 72.0% in studies where patients received intensification of insulin therapy (Table [3](#jdi12605-tbl-0003){ref-type="table-wrap"}). In one study comparing high and low mixtures[30](#jdi12605-bib-0030){ref-type="ref"}, the incidence of hypoglycemia was considerably higher, at up to 90%. The incidence of nocturnal hypoglycemia ranged from 0 to 47.2% among all studies. Severe/major hypoglycemia, where reported, was rare, ranging from 0 to 7% among all studies (0% in most studies). Unsurprisingly, the incidence of hypoglycemia was generally much higher in studies where assessment of hypoglycemia included undocumented hypoglycemia compared with studies where assessment only included documented hypoglycemia.

In all but one[17](#jdi12605-bib-0017){ref-type="ref"} of the 14 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} reporting data, bodyweight/BMI increased from baseline to end‐point after treatment with premixed insulin analogs; the increase was generally greater with insulin initiation than with insulin intensification. Mean/least squares mean bodyweight changes ranged from +0.62 to +4.09 kg among all 10 studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [21](#jdi12605-bib-0021){ref-type="ref"}, [22](#jdi12605-bib-0022){ref-type="ref"}, [23](#jdi12605-bib-0023){ref-type="ref"}, [25](#jdi12605-bib-0025){ref-type="ref"}, [27](#jdi12605-bib-0027){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [30](#jdi12605-bib-0030){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} reporting data, +1.2 to +4.09 kg in studies where patients received initiation of insulin therapy, and +0.62 to +1.94 kg in studies where patients received intensification of insulin therapy. Mean BMI changes ranged from −0.3 to +6.1 kg/m^2^ among the four studies[17](#jdi12605-bib-0017){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [24](#jdi12605-bib-0024){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"} reporting data.

Premixed insulin analogs vs Basal insulin {#jdi12605-sec-0024}
-----------------------------------------

Two studies[21](#jdi12605-bib-0021){ref-type="ref"}, [31](#jdi12605-bib-0031){ref-type="ref"} reported data comparing premixed insulin analogs with basal insulin. In the study reported by Lee *et al*.[31](#jdi12605-bib-0031){ref-type="ref"}, treatment with a premixed insulin analog (once or twice daily) was associated with more pronounced decreases from baseline in HbA1c and a slightly higher proportion of patients attaining the HbA1c target of ≤7% than treatment with basal insulin. In the study reported by Yang *et al*.[21](#jdi12605-bib-0021){ref-type="ref"}, treatment with a premixed insulin analog was found to be non‐inferior to treatment with basal insulin on the basis of the HbA1c change from baseline. Other outcomes, including the incidence of hypoglycemia, were not significantly different between the two treatment groups.

Premixed insulin analogs vs Basal--bolus insulin {#jdi12605-sec-0025}
------------------------------------------------

Seven studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"}, [17](#jdi12605-bib-0017){ref-type="ref"}, [19](#jdi12605-bib-0019){ref-type="ref"}, [20](#jdi12605-bib-0020){ref-type="ref"}, [29](#jdi12605-bib-0029){ref-type="ref"}, [32](#jdi12605-bib-0032){ref-type="ref"} reported data comparing premixed insulin analogs with basal--bolus insulin. In all of these studies, the change from baseline in HbA1c was, in general, not significantly different between the premixed insulin analog and basal--bolus groups, with one study showing non‐inferiority on the basis of this comparison[32](#jdi12605-bib-0032){ref-type="ref"}. Another showed a significantly greater decrease in HbA1c in the premixed insulin analog group compared with the basal--bolus group.[16](#jdi12605-bib-0016){ref-type="ref"} Likewise, other outcomes, including the incidence of hypoglycemia and weight/BMI gain, were not significantly different between groups (or favored the premixed insulin analog group), except in the study reported by Hirao *et al*.[20](#jdi12605-bib-0020){ref-type="ref"}, where the increase in BMI was significantly greater in the premixed insulin analog group compared with the basal--bolus insulin group.

Premixed insulin analogs vs Premixed human insulin {#jdi12605-sec-0026}
--------------------------------------------------

Two studies[18](#jdi12605-bib-0018){ref-type="ref"}, [28](#jdi12605-bib-0028){ref-type="ref"} reported data comparing premixed insulin analogs with premixed human insulin. In the study reported by Zhang *et al*.[18](#jdi12605-bib-0018){ref-type="ref"}, the change from baseline in HbA1c was numerically similar between groups; however, the incidence of hypoglycemia was numerically lower in the premixed insulin analog group compared with the premixed human insulin group. In the study reported by Yamada *et al*.[28](#jdi12605-bib-0028){ref-type="ref"}, the change from baseline to end‐point in HbA1c was significantly greater in the premixed insulin analog group than in the premixed human insulin group. Other outcomes were numerically similar or not significantly different between groups.

Premixed insulin analogs: East Asian vs Caucasian {#jdi12605-sec-0027}
-------------------------------------------------

Two studies[15](#jdi12605-bib-0015){ref-type="ref"}, [16](#jdi12605-bib-0016){ref-type="ref"} reported data for East Asian and Caucasian patients. In the study reported by Ji *et al*.[15](#jdi12605-bib-0015){ref-type="ref"}, there were no significant differences between races for any of the outcomes. However, numerical differences between races included the proportion of patients attaining the HbA1c target (higher in Caucasians), total daily insulin dose (lower in East Asians), the overall and nocturnal incidence of hypoglycemia (lower in East Asians), and bodyweight gain (lower in East Asians). In the study reported by Jeong *et al*.[16](#jdi12605-bib-0016){ref-type="ref"}, statistical comparisons were not made between the East Asian and Caucasian groups. The proportion of patients attaining HbA1c targets was numerically similar between East Asians and Caucasians. Numerical differences between races included the change from baseline to end‐point in HbA1c (slightly more pronounced in East Asians), total daily insulin dose (lower in East Asians), the overall and nocturnal incidence of hypoglycemia (lower in East Asians), and bodyweight gain (lower in East Asians).

Discussion {#jdi12605-sec-0028}
==========

This is the first systematic review to examine the efficacy and safety of premixed insulin analogs in East Asians with type 2 diabetes. The results from the randomized controlled trials included in the present review show that premixed insulin analogs can improve glycemic control in the context of both initiation or intensification of insulin therapy. Furthermore, the magnitude of improvement and the safety profile appear to be similar to those associated with basal or basal--bolus insulin therapy. The evidence from studies reporting data for East Asians and Caucasians was limited, but suggests that dosing, efficacy and safety profiles of premixed insulin analogs might differ slightly as a result of race/ethnicity and/or cultural factors. Taken together, these results support the current use of premixed insulin analogs for managing type 2 diabetes in East Asians.

The results of the present systematic review show that premixed insulin analogs can improve glycemic control, regardless of the type of premixed insulin used, the ratio of rapid‐ to intermediate‐acting insulin, the treatment regimen or the duration of treatment. Furthermore, the studies comparing premixed insulin analogs with other insulin treatments consistently showed that improvements in glycemic control were either numerically similar between groups or favored the premixed insulin analog group. These findings therefore suggest that premixed insulin analogs have an efficacy profile that is not different to those for other insulin treatments in East Asians with type 2 diabetes.

Consistent with the efficacy findings, the studies comparing premixed insulin analogs with other insulin treatments showed that the incidence of hypoglycemia and bodyweight/BMI gain were generally numerically similar between groups. These findings suggest that premixed insulin analogs have a safety profile that is not different to those for other insulin treatments in East Asians with type 2 diabetes. The findings from several studies involving primarily Caucasian populations show that hypoglycemia is more common with twice‐daily premixed insulin than with basal insulin[36](#jdi12605-bib-0036){ref-type="ref"}, [37](#jdi12605-bib-0037){ref-type="ref"}, [38](#jdi12605-bib-0038){ref-type="ref"}. None of the studies identified in the present review specifically compared these two regimens; hence, additional studies are required to determine if twice‐daily premixed insulin increases the rate of hypoglycemia relative to basal insulin in East Asians with type 2 diabetes. Nevertheless, from the available evidence, the apparent similarities in efficacy and safety between premixed insulin analogs and other insulin treatments might reassure East Asian physicians and patients (e.g., patients with consistent daily routines, and/or those who prefer to avoid the burden of frequent blood glucose monitoring and/or injections) who are attracted to the possibility of less complicated regimens that premixed insulin analogs can provide.

The studies identified in the present systematic review consistently reported improvements in glycemic control after both initiation and intensification of insulin therapy with premixed insulin analogs. As expected, the improvements in glycemic control were generally greater for initiation vs intensification with premixed insulin analogs (and indeed comparator treatments). Likewise, bodyweight/BMI gain was greater for initiation vs intensification with premixed insulin analogs. Nevertheless, these findings support the use of premixed insulin analogs in both initiation and intensification of insulin therapy in East Asians.

There were several numerical differences in the efficacy and safety findings between East Asians and Caucasians treated with premixed insulin analogs. Specifically, total daily insulin dose, the overall and nocturnal incidence of hypoglycemia, and bodyweight gain were lower in East Asians than in Caucasians treated with premixed insulin analogs. In one study[16](#jdi12605-bib-0016){ref-type="ref"} reporting data, the improvement in HbA1c was also slightly more pronounced in East Asians, whereas in the other study[15](#jdi12605-bib-0015){ref-type="ref"} reporting data, the proportion of patients attaining the HbA1c target was higher among Caucasians. As both studies were *post‐hoc* analyses, and therefore not sufficiently powered, statistical comparisons between races were generally not carried out. Some of the numerical differences might be at least in part explained by differences in dose between East Asians and Caucasians (e.g., those for hypoglycemia and bodyweight); however, race/ethnicity‐related factors cannot be ruled out, and, therefore, might need to be considered in the prescription of premixed insulin analogs.

We acknowledge that our systematic review has a number of limitations. Specifically, there was, in some cases, considerable variability between studies in eligibility criteria, duration of treatment, type of treatment (both active and control) and treatment regimens. This variability limited the possibility for higher‐level comparisons; for example, of outcomes by treatment duration and so on. Other limitations include the small sample size in some studies, the (generally unavoidable) lack of blinding in all studies, and the fact that just two studies compared efficacy and safety between East Asians and Caucasians. Furthermore, as the studies comparing outcomes between East Asians and Caucasians were subanalyses, the results must be seen as hypothesis‐generating rather than conclusive. We restricted our review to studies comparing premixed insulin with traditional insulin therapies and did not include glucagon‐like peptide‐1 receptor agonists, which can be combined with basal insulin. However, to our knowledge, no published head‐to‐head studies have compared premixed insulin with basal insulin combined with a glucagon‐like peptide‐1 agonist in East Asians/Asians with type 2 diabetes. Therefore, the comparative efficacy and safety of these regimens is yet to be confirmed. Finally, we did not identify any eligible studies reporting on the use of the newly available insulin analog mix, insulin degludec/insulin aspart, in East Asians with type 2 diabetes. A pan‐Asian study of patients with type 2 diabetes showed that changes in HbA1c and rates of hypoglycemia after 26 weeks of treatment with BIAsp or insulin degludec/insulin aspart were not significantly different between treatment groups, whereas FPG control was significantly better among patients treated with insulin degludec/insulin aspart[39](#jdi12605-bib-0039){ref-type="ref"}. Nevertheless, the present systematic review does have a number of noteworthy strengths, including that all studies were randomized controlled trials considered to have a low or unclear risk of bias for most categories, the lack of language restrictions, the inclusion of all types of premixed insulin analogs, and the inclusion of studies on both the initiation and intensification of insulin therapy.

In conclusion, the results of the present systematic review highlight that premixed insulin analogs can be a simple and effective means of treating type 2 diabetes in East Asians, with a safety profile that is generally similar to that of basal and basal--bolus insulin. Clearly, management of type 2 diabetes should always be customized on a patient‐by‐patient basis. To this end, treatment with premixed insulin analogs might be particularly well suited to certain East Asian patients who prefer a less complex regimen than those required for some other insulin treatments.
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